Bifidobacterium lactis Probio-M8 relieved acute respiratory tract infections in children possibly by modulating the gut microbes and metabolites

Respiratory tract infections constitute a significant global public health concern, accounting for around 20 % of child fatalities worldwide. Modulating the gut microbiota have the potential to serve as a promising strategy for both the prevention and treatment of respiratory infections. According to our prior research, the consumption of Bifidobacterium lactis Probio-M8 can notably enhance symptoms associated with respiratory tract infections in infants and young children. The current study is a follow-up work aimed at exploring the functional role of the gut microbes in the observed beneficial effects. We analyzed the fecal metagenomes of patients in both the probiotic group (n = 50) and the placebo group (n = 49). The results showed that Probio-M8 intervention may regulate the host inflammatory response by regulating the balance of intestinal microorganisms, bioactive metabolites and related pathways. Provides new insights into the study of probiotics in alleviating diseases related to the gut-lung axis.